Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Reporting date: June 21, 2022; the filing was signed June 24, 2022. The filing reports results of the annual stockholders’ meeting and approval of an amendment to the company’s equity incentive plan.
Business Context and Reporting Period
Arcturus Therapeutics Holdings Inc. is a Delaware corporation headquartered in San Diego, California, with common stock traded on Nasdaq under the symbol ARCT. The filing does not provide quarterly or annual operating results.
Key Financial and Capital Metrics
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
- The filing does not disclose a financial forecast or changes in financial condition.
Material Changes and Corporate Actions
- Stockholders approved an amendment to the Amended and Restated 2019 Omnibus Equity Incentive Plan.
- The amendment increases shares available for issuance under the plan by 3,750,000 shares.
- Annual award limits for non-employee directors increased from $500,000 to $2,000,000 for newly appointed directors, the lead independent director, and a non-employee chair, and to $1,000,000 for other non-employee directors. These limits include awards granted under and outside the plan.
- All seven nominated directors were elected: Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Edward W. Holmes, Magda Marquet, and Jing L. Marantz.
- Named executive officer compensation was approved on a non-binding advisory basis.
- Stockholders favored annual advisory votes on executive compensation. The Board determined that such votes will occur every year until the next say-on-frequency vote.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Voting Results and Other Matters
Of 26,418,965 shares entitled to vote, 20,945,705 shares were represented at the meeting, constituting a quorum. The equity plan amendment passed with 9,375,429 votes for, 8,044,751 against, and 286,830 abstentions, excluding broker non-votes.
The filing includes the amended and restated 2019 Omnibus Equity Incentive Plan as Exhibit 10.1. The filing does not describe guidance, management’s operating outlook, contingencies, litigation, or unusual financial items.
Important Facts for Investors to Verify
- Review the full amended equity incentive plan to assess potential future dilution and the scope of director compensation limits.
- Confirm the company’s current share reserve and outstanding equity awards in subsequent periodic filings.
- Verify that annual say-on-pay voting remains the Board’s stated policy until the next frequency vote.
- Review subsequent filings for any financial effects associated with equity compensation or changes in director and executive awards.